176 related articles for article (PubMed ID: 11912398)
1. Decreased suburethral prostatic microvessel density in finasteride treated prostates: a possible mechanism for reduced bleeding in benign prostatic hyperplasia.
Hochberg DA; Basillote JB; Armenakas NA; Vasovic L; Shevchuk M; Pareek G; Fracchia JA
J Urol; 2002 Apr; 167(4):1731-3. PubMed ID: 11912398
[TBL] [Abstract][Full Text] [Related]
2. Effect of finasteride treatment on suburethral prostatic microvessel density in patients with hematuria related to benign prostate hyperplasia.
Memis A; Ozden C; Ozdal OL; Guzel O; Han O; Seckin S
Urol Int; 2008; 80(2):177-80. PubMed ID: 18362489
[TBL] [Abstract][Full Text] [Related]
3. The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients.
Pareek G; Shevchuk M; Armenakas NA; Vasovic L; Hochberg DA; Basillote JB; Fracchia JA
J Urol; 2003 Jan; 169(1):20-3. PubMed ID: 12478093
[TBL] [Abstract][Full Text] [Related]
4. Transurethral Resection of Prostate and Bleeding: A Prospective, Randomized, Double-Blind Placebo-Controlled Trial to See the Efficacy of Short-Term Use of Finasteride and Dutasteride on Operative Blood Loss and Prostatic Microvessel Density.
Bansal A; Arora A
J Endourol; 2017 Sep; 31(9):910-917. PubMed ID: 28650680
[TBL] [Abstract][Full Text] [Related]
5. Expression of basic fibroblast growth factor and its receptors FGFR1 and FGFR2 in human benign prostatic hyperplasia treated with finasteride.
Sáez C; González-Baena AC; Japón MA; Giráldez J; Segura DI; Rodríguez-Vallejo JM; González-Esteban J; Miranda G; Torrubia F
Prostate; 1999 Jul; 40(2):83-8. PubMed ID: 10386468
[TBL] [Abstract][Full Text] [Related]
6. Effects of benign prostatic hyperplasia and finasteride therapy on prostatic blood flow in dogs.
Angrimani DSR; Silvestrini GR; Brito MM; Abreu RA; Almeida LL; Vannucchi CI
Theriogenology; 2018 Jul; 114():103-108. PubMed ID: 29605575
[TBL] [Abstract][Full Text] [Related]
7. The Effect of Two Weeks Preoperative Finasteride Therapy in Reducing Prostate Vascularity.
Khwaja MA; Nawaz G; Muhammad S; Jamil MI; Faisal M; Akhter S
J Coll Physicians Surg Pak; 2016 Mar; 26(3):213-5. PubMed ID: 26975954
[TBL] [Abstract][Full Text] [Related]
8. A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride.
Foley SJ; Soloman LZ; Wedderburn AW; Kashif KM; Summerton D; Basketter V; Holmes SA
J Urol; 2000 Feb; 163(2):496-8. PubMed ID: 10647664
[TBL] [Abstract][Full Text] [Related]
9. Finasteride targets prostate vascularity by inducing apoptosis and inhibiting cell adhesion of benign and malignant prostate cells.
Sutton MT; Yingling M; Vyas A; Atiemo H; Borkowski A; Jacobs SC; Kyprianou N
Prostate; 2006 Aug; 66(11):1194-202. PubMed ID: 16652387
[TBL] [Abstract][Full Text] [Related]
10. Randomized, placebo-controlled trial showing that finasteride reduces prostatic vascularity rapidly within 2 weeks.
Donohue JF; Hayne D; Karnik U; Thomas DR; Foster MC
BJU Int; 2005 Dec; 96(9):1319-22. PubMed ID: 16287453
[TBL] [Abstract][Full Text] [Related]
11. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
Lepor H; Williford WO; Barry MJ; Haakenson C; Jones K
J Urol; 1998 Oct; 160(4):1358-67. PubMed ID: 9751354
[TBL] [Abstract][Full Text] [Related]
12. Role of finasteride in the treatment of recurrent hematuria secondary to benign prostatic hyperplasia.
Carlin BI; Bodner DR; Spirnak JP; Resnick MI
Prostate; 1997 May; 31(3):180-2. PubMed ID: 9167770
[TBL] [Abstract][Full Text] [Related]
13. Comparison of microvessel densities in rat prostate tissues treated with finasteride, bicalutamide and surgical castration: a preliminary study.
Kaya C; Ozyurek M; Turkeri LN
Int J Urol; 2005 Feb; 12(2):194-8. PubMed ID: 15733115
[TBL] [Abstract][Full Text] [Related]
14. Clinical predictors in the use of finasteride for control of gross hematuria due to benign prostatic hyperplasia.
Kearney MC; Bingham J; Bergland R; Meade-D'Alisera P; Puchner PJ
J Urol; 2002 Jun; 167(6):2489-91. PubMed ID: 11992064
[TBL] [Abstract][Full Text] [Related]
15. Treatment of benign prostatic hyperplasia with 5-alpha-reductase inhibitor: morphological changes in patients who fail to respond.
Montironi R; Valli M; Fabris G
J Clin Pathol; 1996 Apr; 49(4):324-8. PubMed ID: 8655710
[TBL] [Abstract][Full Text] [Related]
16. Lack of correlation between prostate-specific antigen density and prostatic shrinkage in response to finasteride therapy.
Kirschenbaum A; Pacheco E; Schuval BJ; Levine AC
World J Urol; 1996; 14(6):360-2. PubMed ID: 8986036
[TBL] [Abstract][Full Text] [Related]
17. Finasteride effects on hypoxia and angiogenetic markers in benign prostatic hyperplasia.
Lekas AG; Lazaris AC; Chrisofos M; Papatsoris AG; Lappas D; Patsouris E; Deliveliotis C
Urology; 2006 Aug; 68(2):436-41. PubMed ID: 16904480
[TBL] [Abstract][Full Text] [Related]
18. [Medical treatment of benign prostatic hyperplasia. The efficacy of finasteride depends on prostatic volume].
Granados Loarca EA
Arch Esp Urol; 1999 Apr; 52(3):201-8. PubMed ID: 10371735
[TBL] [Abstract][Full Text] [Related]
19. The effects of finasteride on hematuria associated with benign prostatic hyperplasia: a preliminary report.
Puchner PJ; Miller MI
J Urol; 1995 Nov; 154(5):1779-82. PubMed ID: 7563345
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia.
Kaplan SA; Holtgrewe HL; Bruskewitz R; Saltzman B; Mobley D; Narayan P; Lund RH; Weiner S; Wells G; Cook TJ; Meehan A; Waldstreicher J;
Urology; 2001 Jun; 57(6):1073-7. PubMed ID: 11377309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
